Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Qiagen purchases stake in Alacris Theranostics

Qiagen purchases stake in Alacris Theranostics

17th January 2011

Qiagen is acquiring a stake in Alacris Theranostics, a German start-up company which specialises in technology for personalised cancer treatments.

Under the terms of the deal, Qiagen will gain an exclusive option for rights to access all biomarkers emerging from Alacris' research, which is based upon an innovative proprietary modelling and analysis system.

This technology is called ModCell and was developed by the Max Planck Institute for Molecular Genetics, allowing researchers to more easily identify relevant genetic markers that can help to inform treatment decisions.

Qiagen expressed confidence that both companies will benefit from this alliance of Alacris' novel technology and Qiagen's global reach and expertise.

Peer Schatz, chief executive officer of the company, said: "Our strategic investment in Alacris expands Qiagen's existing broad biomarker discovery and validation initiatives and is designed to expand our QIAsymphony-based personalised healthcare and pharma development assay portfolio."

According to Qiagen's most recent financial report in November 2010, the company saw double-digit year-on-year sales growth during the first nine months of last year.ADNFCR-8000103-ID-800346422-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.